ArticleACS central science2018
PotentialNet for Molecular Property Prediction.
Article in ACS central science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
165 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review of molecular representation learning foundation models.Briefings in bioinformatics · 2026Pooled it
- Systematic review on the application of machine learning to quantitative structure-activity relationship modeling against Plasmodium falciparum.Molecular diversity · 2022Pooled it
- Protein Science Meets Artificial Intelligence: A Systematic Review and a Biochemical Meta-Analysis of an Inter-Field.Frontiers in bioengineering and biotechnology · 2022Pooled it
- Target discovery and drug design in the era of artificial intelligence.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Persistent Local Laplacian Prediction of Protein-Ligand Binding Affinities.Journal of chemical information and modeling · 2026Article
- Physical priors improve performance of structure-based binding affinity models.bioRxiv : the preprint server for biology · 2026Article
- MSCA-PLA: multi-scale cross-attention with differentiable pooling for protein-ligand binding affinity prediction.Molecular diversity · 2026Article
- Article
- Machine Learning for RNA-Targeting Drug Design.Journal of chemical information and modeling · 2026Review
- Graph-based drug-target interaction modeling: from representation learning to output-driven drug discovery.Briefings in bioinformatics · 2026Review
- Dynamics-enhanced molecular property prediction guided by deep learning.PLoS computational biology · 2026Article
- DVNDTA: a dual virtual node based heterogeneous interaction model for accurate prediction of drug-target affinity.BMC bioinformatics · 2026Article
- Structural Knowledge Is What Matters in Protein-Ligand Binding Affinity Prediction.Molecules (Basel, Switzerland) · 2026Article
- A unified multi-scale deep learning framework for molecular property prediction that bridges molecular structures and fingerprinting.Communications chemistry · 2026Article
- Generative Artificial Intelligence-Empowered Virtual Evolution of Enzyme with the VERnet Model.ACS catalysis · 2026Article
- Graph-Aware AURALSTM: An Attentive Unified Representation Architecture with BiLSTM for Enhanced Molecular Property Prediction.Molecular diversity · 2026Article
- Machine Learning Prediction of Laccase-Catalyzed Oxidation of Aromatic Compounds Using Curated Enzyme-Specific Datasets.Journal of computational chemistry · 2026Article
- Integrated Computer-Aided Drug Design: Advances in GPCR Natural Ligand Discovery.Cell biochemistry and biophysics · 2026Review
- Review
- PredictRx: AI based decision support tool for molecular screening for breast cancer drug recommendation.Frontiers in artificial intelligence · 2026Article
105 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The arc of drug discovery entails a multiparameter optimization problem spanning vast length scales. The key parameters range from solubility (angstroms) to protein-ligand binding (nanometers) to
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.